hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Inclusion Criteria: * 1\. Signed and dated written IRB approved informed consent; * 2\. Males or females aged ≥18 years; * 3\. Subjects with breast, lung or pancreatic carcinoma who are at high risk of relapse post definitive therapy at least 4 and no more than 24 weeks from completion of definitive therapy at the time of signing informed consent as described below for each indication: * Breast carcinoma: * Lung carcinoma: * Pancreatic carcinoma: * Head and neck squamous cell carcinoma: * Ovarian cancer: * Colorectal cancer * Gastric and esophageal cancer * Hepatocellular carcinoma Exclusion Criteria: * 1\. Previous treatment wth any TERT or IL-12 containing therapy, or any other DNA immunotherapy; * 2\. Any concurrent condition requiring the continued or anticipated use of systemic steroids (excluding non-systemic inhaled, topical skin and/or eye drop-containing corticosteroids) or immunosuppressive therapy (excludes low dose methotrexate). All other systemic corticosteroids must be discontinued at least 4 weeks prior to first Study Treatment; * 3\. Administration of any vaccine within 4 weeks of the first study treatment